Cargando…
Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.
Flavone acetic acid (FAA), 8.6 gm-2 has been administered by 6h intravenous infusion to 19 patients with advanced colorectal carcinoma and 15 patients with advanced malignant melanoma. The drug associated toxicity was generally mild and as predicted from the phase I study. No responses were seen in...
Autores principales: | Kerr, D. J., Maughan, T., Newlands, E., Rustin, G., Bleehen, N. M., Lewis, C., Kaye, S. B. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1989
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247346/ https://www.ncbi.nlm.nih.gov/pubmed/2803908 |
Ejemplares similares
-
Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data.
por: Maughan, T. S., et al.
Publicado: (1992) -
Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. IV: Pharmacokinetics and toxicity of flavone acetic acid and its metabolites.
por: Stratford, M. R., et al.
Publicado: (1993) -
Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production.
por: Thomsen, L. L., et al.
Publicado: (1992) -
Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies.
por: Haworth, C., et al.
Publicado: (1993) -
Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
por: Kerr, D. J., et al.
Publicado: (1995)